Adams Alex J, Eid Deeb D
Idaho Division of Financial Management, Eagle, ID 83616, United States of America.
Ferris State University College of Pharmacy, Affiliate Preceptor, Grand Rapids, MI 49501, United States of America.
Explor Res Clin Soc Pharm. 2023 Mar;9:100244. doi: 10.1016/j.rcsop.2023.100244. Epub 2023 Mar 14.
The U.S federal government leveraged emergency authority to allow pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) during the COVID-19 pandemic. While heralded by pharmacy associations, the FDA framework included restrictions that arguably ran counter to clinical guidelines and evidence-based research and recommendations. These restrictions will limit the utility of pharmacist prescriptive authority for Paxlovid in practice. The experience of Paxlovid prescribing and a similar recent federal action illustrate the challenges inherent in federal oversight of pharmacist prescriptive authority. While initially more difficult to navigate for stakeholders, working with state legislatures and state boards of pharmacy has much stronger long-term potential to enable broad pharmacist prescriptive authority and benefit patient care. This commentary uses Idaho's pharmacist prescribing regulations as a comparison to the federal actions.
在新冠疫情期间，美国联邦政府利用紧急权力允许药剂师开具帕罗韦德（奈玛特韦和利托那韦）。尽管得到了药学协会的赞誉，但美国食品药品监督管理局（FDA）的框架包含一些限制，这些限制可以说与临床指南以及循证研究和建议背道而驰。这些限制将在实践中限制药剂师对帕罗韦德的处方权效用。帕罗韦德处方的经验以及近期一项类似的联邦行动说明了联邦对药剂师处方权进行监督所固有的挑战。虽然一开始利益相关者更难应对，但与州立法机构和州药房委员会合作在长期内更有潜力实现广泛的药剂师处方权并惠及患者护理。本评论将爱达荷州药剂师处方规定与联邦行动进行比较。
